MINJUVI
Google image searchProduct monograph
Active ingredient
tafasitamab, 200 MG/VIAL
DIN: 02518627
Dosage form(s): POWDER FOR SOLUTION
Route(s) of administration: INTRAVENOUS
Description: SINGLE USE VIAL
Schedule: Prescription / Schedule D
Company: INCYTE CORPORATION
Date: 06-DEC-2021
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FX — Other monoclonal antibodies and antibody drug conjugates (ATC, ATC/DDD)
- L01FX12 — TAFASITAMAB (ATC/DDD)
